<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7315394\results\search\testTrace\results.xml">
  <result pre="difficulty breathing. To date, there is no specific vaccine or" exact="treatment" post="proven effective against this viral disease. Early and accurate"/>
  <result pre="treatment proven effective against this viral disease. Early and accurate" exact="diagnosis" post="of COVID-19 is thus critical to curbing its spread"/>
  <result pre="disease diagnosis. Here, as part of the effort to expand" exact="screening" post="capacity, we review advances and challenges in the rapid"/>
  <result pre="screening capacity, we review advances and challenges in the rapid" exact="detection" post="of COVID-19 by targeting nucleic acids, antigens, or antibodies."/>
  <result pre="COVID-19 can spread from person-to-person and animal, and transmission of" exact="infection" post="may occur with exposure to symptomatic patients or asymptomatic"/>
  <result pre="while structural proteins are responsible for virion assembly and viral" exact="infection" post="[12, 13]. The M and E proteins are required"/>
  <result pre="2019-nCoV develop mild respiratory symptoms and fever, 5-6 days after" exact="infection" post="(mean incubation period, 5-6 days; range, 1-14 days). People"/>
  <result pre="against COVID-19. Thus, there is an urgent need for rapid" exact="detection" post="to prevent further spread, to reduce the intensity of"/>
  <result pre="review, we concentrate on the most significant developments in 2019-nCoV" exact="detection" post="and provide an overview of medical treatments and vaccines"/>
  <result pre="induced in response to viral infection. The most common 2019-nCoV" exact="detection" post="methods include viral nucleic acid detection and serum antibody"/>
  <result pre="The most common 2019-nCoV detection methods include viral nucleic acid" exact="detection" post="and serum antibody (IgG or IgM) detection. A confirmed"/>
  <result pre="samples (1000-3000 copies/mL) within 10â€‰min, indicating the potential for rapid" exact="detection" post="of an outbreak in the clinic. For 1â€‰h sequencing"/>
  <result pre="provides fast, low-cost DNA sequencing, it is not suitable for" exact="detection" post="in clinics. On the other hand, the HTS strategy"/>
  <result pre="nucleic acids extracted from 2019-nCoV specimens qualitatively. Positive results indicate" exact="infection" post="with 2019-nCoV. RT-PCR is an advanced technique for coronavirus"/>
  <result pre="infection with 2019-nCoV. RT-PCR is an advanced technique for coronavirus" exact="detection" post="because of its optimized sensitivity, specificity, and simplicity for"/>
  <result pre="2019-nCoV test systems: cobasÂ® 6800 and cobasÂ® 8800 (approved in" exact="testing" post="patient samples by the US FDA), which can process"/>
  <result pre="and can process up to 4128 results in 24â€‰h, boosting" exact="screening" post="capacity to help restrain the sudden growing epidemic in"/>
  <result pre="epidemic in the USA. RT-PCR is widely applicable to 2019-nCoV" exact="detection" post="in the clinic, but limitations of this technology are"/>
  <result pre="melting with the aid of enzymes. Combined with a visual" exact="detection" post="platform, such as a lateral flow assay (LFA) or"/>
  <result pre="dyes, LAMP and RPA have been widely employed in viral" exact="detection" post="kits. LAMP is a rapid, one-step amplification technique that"/>
  <result pre="be detected [38]. RT-LAMP offers improved sensitivity and specificity in" exact="screening" post="SARS-CoV, HCoV-NL63, and MERS-CoV compared to conventional real-time RT-PCR"/>
  <result pre="template. Results require a 15â€‰min reaction time at 65Â°C, and" exact="detection" post="sensitivity is comparable to that of the TaqMan-based qPCR"/>
  <result pre="the nsp3, S, and N genes of 2019-nCoV using colorimetric" exact="detection" post="[43]. The sensitivity of this RT-LAMP assay was 100"/>
  <result pre="DNA target amplification, RPA formats have been developed for the" exact="detection" post="of RNA targets (RT-RPA) by adding a reverse transcriptase"/>
  <result pre="transcriptase enzyme to reaction mixtures [48]. Because RPA- (RT-RPA-) based" exact="detection" post="achieves more rapid and sensitive results and operates efficiently,"/>
  <result pre="CRISPR/Cas systems have also been widely used in nucleic acid" exact="detection" post="with fluorescent and colorimetric signals [56]. There are mainly"/>
  <result pre="and RNA-targeting CRISPR effector, Cas13a (Figure 4(a)) [57, 58]. The" exact="detection" post="system is highly sensitive and specific because it is"/>
  <result pre="detection. Subsequently, they developed an enhanced SHERLOCK version 2 (SHERLOCKv2)" exact="detection" post="system with a 3.5-fold improvement in detection sensitivity and"/>
  <result pre="version 2 (SHERLOCKv2) detection system with a 3.5-fold improvement in" exact="detection" post="sensitivity and lateral flow readout. SHERLOCKv2 has been used"/>
  <result pre="in clinical samples, showing great potential for multiplexable, portable, rapid" exact="detection" post="of nucleic acids [59]. Recently, they combined RT-RPA technology"/>
  <result pre="The analysis is performed at 37Â°C and 42Â°C, and its" exact="detection" post="sensitivity is ten copies per microliter of input, exhibiting"/>
  <result pre="endonuclease-targeted CRISPR trans reporter (DETECTR), with attomolar sensitivity for DNA" exact="detection" post="(Figure 4(a)) [61]. DETECTR was also validated with clinical"/>
  <result pre="validated with clinical samples, showing the capacity for rapid, specific" exact="detection" post="of human papillomavirus (HPV) [61]. Recently, DETECTR was investigated"/>
  <result pre="results were visible to the unaided eye. The limit of" exact="detection" post="for ORF1ab was ten copies/Î¼L. The advantages of this"/>
  <result pre="be validated with clinical samples before commercialization. Another DETECTR-based 2019-nCoV" exact="detection" post="strategy was developed by Chiu's lab [63]. They employed"/>
  <result pre="low-cost, and accurate (100% specific vs. 90% specific for qRT-PCR)" exact="detection" post="of 2019-nCoV in respiratory swab samples. Realistically, CRISPR/Cas-based 2019-nCoV"/>
  <result pre="detection of 2019-nCoV in respiratory swab samples. Realistically, CRISPR/Cas-based 2019-nCoV" exact="detection" post="technology is highly specific, rapid, and low cost, but"/>
  <result pre="technology is highly specific, rapid, and low cost, but the" exact="detection" post="strategy also needs to be validated using clinical samples."/>
  <result pre="including drug screening, tissue engineering, disease diagnostics, and nucleic acid" exact="detection" post="[66, 67]. Based on its portability and ultralow sample"/>
  <result pre="conducted with droplets generated by the microfluidic chip. However, the" exact="detection" post="of fluorescent signals in droplets requires special instruments, such"/>
  <result pre="pressure delays liquid evaporation but complicates the devices and increases" exact="testing" post="costs. Digital LAMP is more compatible with microfluidics than"/>
  <result pre="at a moderate temperature. This simplifies microfluidic devices and reduces" exact="testing" post="costs. Many microfluidic devices have been reported for nucleic"/>
  <result pre="costs. Many microfluidic devices have been reported for nucleic acid" exact="detection" post="using digital LAMP, such as self-digitization chips, self-priming compartmentalization"/>
  <result pre="fabricated a spiral chip with 1200 chambers (9.6â€‰nL) for pathogen" exact="detection" post="(Figure 5(a)â€&quot;(c)). This spiral chip operated at 65Â°C without"/>
  <result pre="acids over four orders of magnitude in concentration with a" exact="detection" post="limit of 87 copies per mL. This portable gadget"/>
  <result pre="applied to detecting 2019-nCoV. Ho et al. developed a modular" exact="detection" post="platform (termed enVision) consisting of an integrated circuit of"/>
  <result pre="an integrated circuit of enzyme-DNA nanostructures for direct and versatile" exact="detection" post="of pathogen nucleic acids from infected cells [75]. Built-in"/>
  <result pre="Antibody As mentioned above, the primary diagnostic methods are virological" exact="detection" post="involving viral nucleic acids. Another approach to detection is"/>
  <result pre="are virological detection involving viral nucleic acids. Another approach to" exact="detection" post="is with serological assays that measure antigens or antibodies"/>
  <result pre="that measure antigens or antibodies present in the host. Such" exact="testing" post="provides vital information about host exposure to 2019-nCoV and"/>
  <result pre="information about host exposure to 2019-nCoV and is useful for" exact="detection" post="and surveillance purposes. For instance, this method greatly helps"/>
  <result pre="used for COVID-19 diagnosis. 2.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Early" exact="diagnosis" post="of 2019-nCoV infection is of utmost importance both for"/>
  <result pre="diagnosis. 2.2.1. Enzyme-Linked Immunosorbent Assay (ELISA) Early diagnosis of 2019-nCoV" exact="infection" post="is of utmost importance both for medical teams to"/>
  <result pre="has proven to be the working â€œgold standardâ€� for laboratory" exact="diagnosis" post="of 2019-nCoV [77]. ELISA is a plate-based assessment method"/>
  <result pre="depend on specific antibodies to bind target antigens and a" exact="detection" post="system to indicate the presence of antigen binding. In"/>
  <result pre="were also other reports of using ELISA to diagnose 2019-nCoV" exact="infection" post="[81, 82]. Each study confirmed the high reproducibility and"/>
  <result pre="generate IgM and IgG antibodies in infected humans. Therefore, the" exact="detection" post="of IgM and IgG antibodies may provide epidemiologists with"/>
  <result pre="IgG antibodies may provide epidemiologists with crucial information on viral" exact="infection" post="of test subjects, allowing them to adjust policies to"/>
  <result pre="from six patients are shown in Figure 6(c). Common 2019-nCoV" exact="detection" post="methods are summarized in Table 1. 2.3. Supplementary Detection"/>
  <result pre="readily identify lung abnormalities in human subjects, thereby enabling early" exact="treatment" post="against COVID-19. CT has demonstrated some common imaging characteristics"/>
  <result pre="use, CT has become an essential tool for the 2019-nCoV" exact="infection" post="diagnosis. From a radiological perspective, the advantages of using"/>
  <result pre="medicine, and stem cell therapy can be potentially used for" exact="treatment" post="or as an adjuvant to reduce the mortality and"/>
  <result pre="upon their immune systems to combat the infection. A full-fledged" exact="treatment" post="plan has yet to emerge, and both academia and"/>
  <result pre="At present, repurposed drugs are the only option available at" exact="treatment" post="centers for COVID-19 patients. As COVID-19 is a viral"/>
  <result pre="the antiviral drug creation strategies. 3.1.1. Entry Inhibitors When an" exact="infection" post="occurs, the virus gains entry into a host cell"/>
  <result pre="(Figure 9(a)). These inhibitors are valuable as therapeutics since blocking" exact="infection" post="early in the life cycle reduces cellular and tissue"/>
  <result pre="development [114]. However, ACE2 stimulators have been used in the" exact="treatment" post="of hypertension, cardiac diseases, and diabetes mellitus to regulate"/>
  <result pre="on ACE2-targeting drugs, and controversial issues that lie beyond the" exact="treatment" post="pathway need to be addressed soon. A small antiviral"/>
  <result pre="virus effect [122â€&quot;124]. Hemagglutinin, a viral cell surface protein, facilitates" exact="infection" post="by undergoing a conformational change when the virus binds"/>
  <result pre="an in vitro study that arbidol may effectively inhibit 2019-nCoV" exact="infection" post="at a concentration of 10-30â€‰Î¼M [128]. Chloroquine, also a"/>
  <result pre="as cell growth and death, blood clotting, inflammation, fertilization, and" exact="infection" post="[103]. Viral entry into host cells requires S protein"/>
  <result pre="breakthrough of antiviral drug design in the mid-1990s for the" exact="treatment" post="of HIV. Most HIV protease inhibitors have found prominent"/>
  <result pre="that has shown an excellent therapeutic effect for chronic pancreatitis" exact="treatment" post="by targeting proteases [113, 151, 152]. Camostat mesylate primarily"/>
  <result pre="camostat mesylate displays an inhibitory effect in mice for SARS-CoV" exact="infection" post="[152]. Recent research by Hoffmann et al. showed a"/>
  <result pre="lung cells, showing potential as a viable option for COVID-19" exact="treatment" post="[113]. Unfortunately, in vitro and in vivo data for"/>
  <result pre="Kong has shown that the combination of lopinavir-ritonavir and ribavirin" exact="treatment" post="for 152 patients against SARS-CoV had an overall favourable"/>
  <result pre="adult patients infected with 2019-nCoV did not benefit from the" exact="treatment" post="[161]. Given such conflicting clinical data, physicians must carefully"/>
  <result pre="inosine and adenosine, and ribavirin has been used in the" exact="treatment" post="of respiratory syncytial virus [168]. It has only one"/>
  <result pre="173]. Ribavirin was initially used in treating SARS; however, ribavirin" exact="treatment" post="lacked an in vitro antiviral effect and caused adverse"/>
  <result pre="hemoglobin levels [174]. However, ribavirin was used as the primary" exact="treatment" post="during the MERS outbreak [175]. In general, clinical studies"/>
  <result pre="the MERS outbreak [175]. In general, clinical studies of ribavirin" exact="treatment" post="for SARS and MERS did not show strong evidence"/>
  <result pre="Favipiravir is a synthetic guanine analog frequently used for influenza" exact="treatment" post="[179]. Structurally, favipiravir is closely related to ribavirin, in"/>
  <result pre="previously, but interestingly, it has been shown to reduce viral" exact="infection" post="of 2019-nCoV [138, 183]. In a clinical study involving"/>
  <result pre="and developed by Gilead Science in 2017 for Ebola virus" exact="infection" post="[186]. Remdesivir needs to be metabolized into its active"/>
  <result pre="It has been demonstrated that remdesivir is effective against MERS-CoV" exact="infection" post="in vivo and 2019-nCoV in vitro [138, 187], showing"/>
  <result pre="and ribavirin have been recommended in the latest guidelines for" exact="diagnosis" post="and treatment of COVID-19, updated on 17 February 2020"/>
  <result pre="have been recommended in the latest guidelines for diagnosis and" exact="treatment" post="of COVID-19, updated on 17 February 2020 [189]. Recent"/>
  <result pre="of action, efficacy, and safety of carolacton as a possible" exact="treatment" post="for COVID-19. On the other hand, ivermectin is originally"/>
  <result pre="to be done to confirm its efficacy and safety for" exact="treatment" post="against COVID-19. Potential drugs for COVID-19 are summarized in"/>
  <result pre="Nanodrug Delivery System Nanomaterials have recently been utilized for the" exact="treatment" post="of diseases such as cancer [198â€&quot;200] and various types"/>
  <result pre="options. However, to the best of our knowledge, no nanoparticle" exact="treatment" post="option has been applied to COVID-19. Nonetheless, results obtained"/>
  <result pre="efficacy in reducing the viral load during early stages of" exact="infection" post="[208, 209]. Another promising biologic drug is convalescent plasma,"/>
  <result pre="it could be used clinically. 3.4. Nutritional Interventions Another supportive" exact="treatment" post="for COVID-19 involves dietary interventions. Various research studies have"/>
  <result pre="Medicine Traditional Chinese medicine (TCM) is considered a prospective supplementary" exact="treatment" post="of COVID-19, due to its impressive performance in treating"/>
  <result pre="of China has published seven editions of the guidelines for" exact="diagnosis" post="and treatment of COVID-19 [25]. Since the fourth version,"/>
  <result pre="has published seven editions of the guidelines for diagnosis and" exact="treatment" post="of COVID-19 [25]. Since the fourth version, a list"/>
  <result pre="different stages of patients: the medical observation period, the clinical" exact="treatment" post="period, and critical condition (details in Table 3) [25]."/>
  <result pre="the Qing Fei Pai Du Decoction is strongly recommended for" exact="treatment" post="of COVID-19 by the NHC of the People's Republic"/>
  <result pre="be an alternative prophylactic approach to COVID-19 and a supplementary" exact="treatment" post="in combination with western medicine to cure COVID-19. 3.6."/>
  <result pre="3.6. Stem Cell Therapy Stem cell therapy is a promising" exact="treatment" post="strategy for degenerative diseases, including Huntington's disease, Parkinson's and"/>
  <result pre="As H7N9 and 2019-nCoV share similar genome structures and corresponding" exact="infection" post="mechanisms, as well as related clinical symptoms (lung failure),"/>
  <result pre="the WHO report. 3.7. Other Treatments Vaccines are another promising" exact="treatment" post="to prevent or cure specific viruses. Currently, there is"/>
  <result pre="who has come into contact with these patients. As such," exact="contact tracing" post="is still a mainstay for disease control. Confirmation can"/>
  <result pre="has come into contact with these patients. As such, contact" exact="tracing" post="is still a mainstay for disease control. Confirmation can"/>
  <result pre="is recommended for suspected COVID-19 cases [242]. Once the primary" exact="diagnosis" post="reveals abnormal chest CT findings, a nucleic acid test"/>
  <result pre="Once the primary diagnosis reveals abnormal chest CT findings, a" exact="nucleic acid test" post="should be performed to confirm whether a patient is"/>
  <result pre="[189]. Chest CT should be performed as a follow-up to" exact="treatment" post="as well [242]. The currently adopted procedure in identifying"/>
  <result pre="restricting movement of residents within their borders. As evidenced globally," exact="social distancing" post="is essential to halt the spread of COVID-19. On"/>
  <result pre="of the pandemic. Practical diagnostic tests have aided management and" exact="contact tracing" post="of COVID-19 cases in hotspot areas. In this regard,"/>
  <result pre="the pandemic. Practical diagnostic tests have aided management and contact" exact="tracing" post="of COVID-19 cases in hotspot areas. In this regard,"/>
  <result pre="obtain valuable information about prior exposure to 2019-nCoV and the" exact="prevalence" post="of infection. These include ELISA and LFA technologies. Serological"/>
  <result pre="prevalence of infection. These include ELISA and LFA technologies. Serological" exact="screening" post="also enables novel vaccines to be assessed and supports"/>
  <result pre="tomography (CT) and transmission electron microscopy (TEM), can boost existing" exact="detection" post="approaches. Notably, there has been a marked increase in"/>
  <result pre="National Health Committee of the People's Republic of ChinaDiagnosis and" exact="treatment" post="guidelines for COVID-19April 2020, http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml 26StrobelE. J.YuA. M.LucksJ. B.High-throughput"/>
  <result pre="of America197774125463546710.1073/pnas.74.12.5463271968 28WangM.FuA.HuB.et al.Nanopore target sequencing for accurate and comprehensive" exact="detection" post="of SARS-CoV-2 and other respiratory viruses2020MedRxiv10.1101/2020.03.04.20029538 29WeiS.WeissZ. R.WilliamsZ.Rapid multiplex"/>
  <result pre="Reviews Microbiology20191729510910.1038/s41579-018-0116-y30442909 31ShenM.ZhouY.YeJ.et al.Recent advances and perspectives of nucleic acid" exact="detection" post="for coronavirusJournal of Pharmaceutical Analysis20201029710110.1016/j.jpha.2020.02.010 32TahamtanA.ArdebiliA.Real-time RT-PCR in COVID-19"/>
  <result pre="simple and multiplex loop-mediated isothermal amplification (LAMP) assay for rapid" exact="detection" post="of SARS-CoVBioChip Journal201913434135110.1007/s13206-019-3404-332226589 40HuangP.WangH.CaoZ.et al.A rapid and specific assay"/>
  <result pre="SARS-CoVBioChip Journal201913434135110.1007/s13206-019-3404-332226589 40HuangP.WangH.CaoZ.et al.A rapid and specific assay for the" exact="detection" post="of MERS-CoVFrontiers in Microbiology20189p. 110110.3389/fmicb.2018.01101 41PyrcK.MilewskaA.PotempaJ.Development of loop-mediated isothermal"/>
  <result pre="in Microbiology20189p. 110110.3389/fmicb.2018.01101 41PyrcK.MilewskaA.PotempaJ.Development of loop-mediated isothermal amplification assay for" exact="detection" post="of human coronavirus-NL63Journal of Virological Methods2011175113313610.1016/j.jviromet.2011.04.02421545810 42YuL.WuS.HaoX.et al.Rapid colorimetric"/>
  <result pre="detection of human coronavirus-NL63Journal of Virological Methods2011175113313610.1016/j.jviromet.2011.04.02421545810 42YuL.WuS.HaoX.et al.Rapid colorimetric" exact="detection" post="of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal"/>
  <result pre="Respiratory Syndrome Coronavirus 2The Journal of Molecular Diagnostics202010.1016/j.jmoldx.2020.03.006 44YangW.DangX.WangQ.et al.Rapid" exact="detection" post="of SARS-CoV-2 using reverse transcription RT-LAMP method2020MedRxiv10.1101/2020.03.02.20030130 45El-TholothM.BauH. H.SongJ.A"/>
  <result pre="of entry2020ChemRxiv10.26434/chemrxiv.11860137.v1 46BabuB.Ochoa-CoronaF. M.ParetM. L.Recombinase polymerase amplification applied to plant" exact="virus detection" post="and potential implicationsAnalytical Biochemistry2018546727710.1016/j.ab.2018.01.02129408177 47LobatoI. M.O'SullivanC. K.Recombinase polymerase amplification:"/>
  <result pre="entry2020ChemRxiv10.26434/chemrxiv.11860137.v1 46BabuB.Ochoa-CoronaF. M.ParetM. L.Recombinase polymerase amplification applied to plant virus" exact="detection" post="and potential implicationsAnalytical Biochemistry2018546727710.1016/j.ab.2018.01.02129408177 47LobatoI. M.O'SullivanC. K.Recombinase polymerase amplification:"/>
  <result pre="al.A portable reverse transcription recombinase polymerase amplification assay for rapid" exact="detection" post="of foot-and-mouth disease virusPLoS One201388, article e7164210.1371/journal.pone.007164223977101 49BoyleD. S.LehmanD."/>
  <result pre="foot-and-mouth disease virusPLoS One201388, article e7164210.1371/journal.pone.007164223977101 49BoyleD. S.LehmanD. A.LillisL.et al.Rapid" exact="detection" post="of HIV-1 proviral DNA for early infant diagnosis using"/>
  <result pre="A.LillisL.et al.Rapid detection of HIV-1 proviral DNA for early infant" exact="diagnosis" post="using recombinase polymerase amplificationMBio20134210.1128/mbio.00135-13 50AmerH. M.Abd el WahedA.ShalabyM. A.AlmajhdiF."/>
  <result pre="50AmerH. M.Abd el WahedA.ShalabyM. A.AlmajhdiF. N.HufertF. T.WeidmannM.A new approach for" exact="diagnosis" post="of bovine coronavirus using a reverse transcription recombinase polymerase"/>
  <result pre="WahedA. A.PatelP.HeidenreichD.HufertF. T.WeidmannM.Reverse transcription recombinase polymerase amplification assay for the" exact="detection" post="of Middle East respiratory syndrome coronavirusPLoS Currents2013510.1371/currents.outbreaks.62df1c7c75ffc96cd59034531e2e8364 52YanT.LiX. N.WangL.et"/>
  <result pre="al.Development of a reverse transcription recombinase-aided amplification assay for the" exact="detection" post="of coxsackievirus A10 and coxsackievirus A6 RNAArchives of Virology201816361455146110.1007/s00705-018-3734-929429036"/>
  <result pre="diseaseTrends in Cardiovascular Medicine20203029310110.1016/j.tcm.2019.03.00530935726 57GootenbergJ. S.AbudayyehO. O.LeeJ. W.et al.Nucleic acid" exact="detection" post="with CRISPR-Cas13a/C2c2Science2017356633643844210.1126/science.aam932128408723 58KellnerM. J.KoobJ. G.GootenbergJ. S.AbudayyehO. O.ZhangF.SHERLOCK: nucleic acid"/>
  <result pre="detection with CRISPR-Cas13a/C2c2Science2017356633643844210.1126/science.aam932128408723 58KellnerM. J.KoobJ. G.GootenbergJ. S.AbudayyehO. O.ZhangF.SHERLOCK: nucleic acid" exact="detection" post="with CRISPR nucleasesNature Protocols201914102986301210.1038/s41596-019-0210-231548639 59GootenbergJ. S.AbudayyehO. O.KellnerM. J.JoungJ.CollinsJ. J.ZhangF.Multiplexed"/>
  <result pre="Protocols201914102986301210.1038/s41596-019-0210-231548639 59GootenbergJ. S.AbudayyehO. O.KellnerM. J.JoungJ.CollinsJ. J.ZhangF.Multiplexed and portable nucleic acid" exact="detection" post="platform with Cas13, Cas12a, and Csm6Science2018360638743944410.1126/science.aaq017929449508 60ZhangF.AbudayyehO. O.JonathanS. G.SHERLOCK,"/>
  <result pre="Cas13, Cas12a, and Csm6Science2018360638743944410.1126/science.aaq017929449508 60ZhangF.AbudayyehO. O.JonathanS. G.SHERLOCK, a protocol for" exact="detection" post="of COVID-19 using CRISPR diagnostics2020https://www.broadinstitute.org/files/publications/special/COVID-19%20detection%20(updated).pdf 61ChenJ. S.MaE.HarringtonL. B.et al.CRISPR-Cas12a"/>
  <result pre="activityScience2018360638743643910.1126/science.aar624529449511 62LuciaC.FedericoP.-B.AlejandraG. C.An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence" exact="detection" post="method based on CRISPR-Cas122020BioRxiv10.1101/2020.02.29.971127 63BroughtonJ. P.DengX.YuG.et al.CRISPR-Cas12-based detection of"/>
  <result pre="SARS-CoV-2 sequence detection method based on CRISPR-Cas122020BioRxiv10.1101/2020.02.29.971127 63BroughtonJ. P.DengX.YuG.et al.CRISPR-Cas12-based" exact="detection" post="of SARS-CoV-2Nature Biotechnology20201510.1038/s41587-020-0513-4 64VogelsteinB.KinzlerK. W.Digital PCRProceedings of the National"/>
  <result pre="a Chip201515377678210.1039/C4LC01158A25431886 75HoN. R. Y.LimG. S.SundahN. R.LimD.LohT. P.ShaoH.Visual and modular" exact="detection" post="of pathogen nucleic acids with enzyme-DNA molecular complexesNature Communications2018913211323810.1038/s41467-018-05733-030104566"/>
  <result pre="application of a rapid IgM-IgG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJournal of Medical Virology202010.1002/jmv.25727 85HosseinyM.KoorakiS.GholamrezanezhadA.ReddyS.MyersL.Radiology perspective of coronavirus disease"/>
  <result pre="W.KeerthisingheP.DuL.SandersonL. E.CrosierK. E.HallC. J.DetrichH. W.WesterfieldM.ZonL. I.Innate immune cells and bacterial" exact="infection" post="in zebrafishMethods in Cell Biology2017138Academic Press3160 101OpreaT. I.BaumanJ. E.BologaC."/>
  <result pre="perspectiveDrug Discovery Today: Therapeutic Strategies201183-4616910.1016/j.ddstr.2011.10.00222368688 102PizzornoA.PadeyB.TerrierO.Rosa-CalatravaM.Drug repurposing approaches for the" exact="treatment" post="of influenza viral infection: reviving old drugs to fight"/>
  <result pre="risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker" exact="treatment" post="in hypertension: a study of 15 990 patientsJournal of"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discovery202061p. 1610.1038/s41421-020-0156-0 136VincentM. J.BergeronE.BenjannetS.et al.Chloroquine is a"/>
  <result pre="136VincentM. J.BergeronE.BenjannetS.et al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirology Journal200521p. 6910.1186/1743-422X-2-69 137KeyaertsE.VijgenL.MaesP.NeytsJ.RanstM. V.In vitro inhibition of"/>
  <result pre="vitroCell Research202030326927110.1038/s41422-020-0282-032020029 139GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBioScience Trends2020141727310.5582/bst.2020.0104732074550 140ColsonP.RolainJ.-M.LagierJ.-C.BrouquiP.RaoultD.Chloroquine"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical Infectious"/>
  <result pre="a Substrate-like Aza-peptide EpoxideJournal of Molecular Biology200535351137115110.1016/j.jmb.2005.09.00416219322 151KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
  <result pre="entryAntiviral Research2015116768410.1016/j.antiviral.2015.01.01125666761 153AshizawaN.HashimotoT.MiyakeT.ShizukuT.ImaokaT.KinoshitaY.Efficacy of camostat mesilate compared with famotidine for" exact="treatment" post="of functional dyspepsia: is camostat mesilate effective?Journal of Gastroenterology"/>
  <result pre="pancreatic pain in rodentsLife Sciences200780211999200410.1016/j.lfs.2007.02.04417433371 156ShiratoK.KawaseM.MatsuyamaS.Middle East respiratory syndrome coronavirus" exact="infection" post="mediated by the transmembrane serine protease TMPRSS2Journal of Virology20138723125521256110.1128/JVI.01890-1324027332"/>
  <result pre="Medicine201143537538810.3109/07853890.2011.57290521501034 159ChuC. M.ChengV. C.HungI. F.et al.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax200459325225610.1136/thorax.2003.01265814985565 160LiuX.WangX.-J.Potential inhibitors"/>
  <result pre="polymerase revealed using high-throughput magnetic tweezersCell Reports20172141063107610.1016/j.celrep.2017.10.00529069588 171KorenG.KingS.KnowlesS.PhillipsE.Ribavirin in the" exact="treatment" post="of SARS: a new trick for an old drug?CMAJ2003168101289129212743076"/>
  <result pre="America200198126895690010.1073/pnas.11108559811371613 173TeH. S.RandallG.JensenD. M.Mechanism of action of ribavirin in the" exact="treatment" post="of chronic hepatitis CGastroenterology &amp;amp; Hepatology20073321822521960835 174TaiD. Y.Pharmacologic treatment"/>
  <result pre="the treatment of chronic hepatitis CGastroenterology &amp;amp; Hepatology20073321822521960835 174TaiD. Y.Pharmacologic" exact="treatment" post="of SARS: current knowledge and recommendationsAnnals Academy of Medicine200736438443"/>
  <result pre="Infectious Diseases20131710e792e79810.1016/j.ijid.2013.07.00223993766 178ChongY. P.SongJ. Y.SeoY. B.ChoiJ. P.ShinH. S.Rapid Response TeamAntiviral" exact="treatment" post="guidelines for Middle East respiratory syndromeInfection &amp;amp; Chemotherapy201547321222210.3947/ic.2015.47.3.21226483999 179AbdelnabiR.MoraisA."/>
  <result pre="RNA polymeraseProceedings of the Japan Academy, Series B201793744946310.2183/pjab.93.02728769016 183CaiQ.YangM.LiuD.et al.Experimental" exact="treatment" post="with favipiravir for COVID-19: an open-label control studyEngineering202010.1016/j.eng.2020.03.007 184ChenC.et"/>
  <result pre="Chinese Centre for Disease Control and PreventionCOVID-19 prevention and control:" exact="diagnosis" post="and treatment2020http://www.chinacdc.cn/en/COVID19/202002/P020200310326343385431.pdf 190AndersonD. E.CuiJ.YeQ.et al.Orthogonal genome-wide screenings in bat"/>
  <result pre="vaccineScience2020367648085285310.1126/science.aba275432079760 208ShenK.YangY.WangT.et al.Diagnosis, treatment, and prevention of 2019 novel coronavirus" exact="infection" post="in children: expertsâ€™ consensus statementWorld Journal of Pediatrics202010.1007/s12519-020-00343-7 209ChenZ.-M.FuJ."/>
  <result pre="expertsâ€™ consensus statementWorld Journal of Pediatrics202010.1007/s12519-020-00343-7 209ChenZ.-M.FuJ. F.ShuQ.et al.Diagnosis and" exact="treatment" post="recommendations for pediatric respiratory infection caused by the 2019"/>
  <result pre="Pediatrics202010.1007/s12519-020-00343-7 209ChenZ.-M.FuJ. F.ShuQ.et al.Diagnosis and treatment recommendations for pediatric respiratory" exact="infection" post="caused by the 2019 novel coronavirusWorld Journal of Pediatrics202010.1007/s12519-020-00345-5"/>
  <result pre="10474310.1016/j.phrs.2020.104743 230HanY.ZhaoM. R.ShiB.SongZ. H.ZhouS. P.HeY.Application of integrative medicine protocols on" exact="treatment" post="of coronavirus disease 2019Chinese Traditional and Herbal Drugs202051878882 231collab:"/>
  <result pre="in Stem Cell2014111210.15419/psc.v1i1.38 234ChenJ.HuC.ChenL.et al.Clinical study of mesenchymal stem cell" exact="treatment" post="for acute respiratory distress syndrome induced by epidemic influenza"/>
  <result pre="919 patientsAmerican Journal of Roentgenology20201710.2214/AJR.20.2303432174129 243Key export products for COVID-19" exact="diagnosis" post="&amp;amp; treatment2020http://iq.chineseembassy.org/chn/gdxw/P020200331083539284917.pdf 244University of Nankai develops rapid test kit2020https://www.thestar.com.my/news/regional/2020/02/18/university-of-nankai-develops-rapid-test-kit"/>
  <result pre="kit to detect coronavirus in 15 mins2020https://news.cgtn.com/news/2020-03-11/Researchers-develop-new-test-kit-to-detect-coronavirus-in-15-mins-OMjPu5DFEk/index.html 246China approves 29-minute" exact="testing" post="kit for new coronavirus2020https://www.chinadaily.com.cn/a/202003/07/WS5e63521aa31012821727d239.html 247S'pore researchers invent Covid-19 test"/>
  <result pre="5 minutes2020https://mothership.sg/2020/03/covid-19-test-how-long/ 248BroughtonJ. P.DengW.FaschingC. L.SinghJ.ChiuC. Y.ChenJ. S.A protocol for rapid" exact="detection" post="of the 2019 novel coronavirus SARS-CoV-2 using CRISPR diagnostics:"/>
  <result pre="structure of 2019-nCoV. Figure 2 High-throughput sequencing and real-time qRT-PCR-based" exact="detection" post="of 2019-nCoV. (a) Four steps of high-throughput sequencing technology."/>
  <result pre="amplification technology. (b, c) RT-LAMP combination with SYBR Green for" exact="detection" post="of 2019-nCoV. The signal of SYBR Green dye was"/>
  <result pre="with permission (b, c) [42], medRxiv. Figure 4 CRISPR-Cas system-based" exact="detection" post="of 2019-nCoV. (a) Mechanism of SHERLOCK and DETECTR for"/>
  <result pre="(b, c) Typical images of lateral flow readout for CRISPR-based" exact="detection" post="at various concentrations [60]. Figure 5 Microfluidic-based detection of"/>
  <result pre="for CRISPR-based detection at various concentrations [60]. Figure 5 Microfluidic-based" exact="detection" post="of 2019-nCoV. (a) Design and fabrication of a spiral"/>
  <result pre="antigens or antibodies to 2019-nCoV. (a) Diagram showing LFA-based quick" exact="detection" post="of 2019-nCoV in an IgM-IgG combined antibody assay. (b)"/>
  <result pre="[97]. Figure 8 Proposed schematic of 2019-nCoV replication and potential" exact="treatment" post="options targeting the coronavirus replication cycle. ACE2: angiotensin-converting enzyme"/>
  <result pre="and gene targets. Method Sampling methods Detection time Accuracy/limit of" exact="detection" post="Advantages Remarks and Ref. Rapid Low cost Sensitive Portable"/>
  <result pre="15â€‰min 92.69% âœ&quot; âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage" exact="detection" post="[243] â€ƒIgG/IgM-AIE-QD Blood 15â€‰min 75% âœ&quot; âœ&quot; âœ&quot; âœ&quot;"/>
  <result pre="Blood 15â€‰min 75% âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage" exact="detection" post="[244] â€ƒIgM-colloidal gold-LFA Blood 15â€‰min Not reported âœ&quot; âœ&quot;"/>
  <result pre="15â€‰min Not reported âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage" exact="detection" post="[245] â€ƒIgG/IgM-ELISA or LFA Blood 29â€‰min 93.1% âœ&quot; âœ&quot;"/>
  <result pre="29â€‰min 93.1% âœ&quot; âœ&quot; âœ&quot; âœ&quot; âœ&quot; Inapplicable to early-stage" exact="detection" post="[246] â€ƒIgG/IgM-colloidal gold-FLA Blood 15-30â€‰min 90% âœ&quot; âœ&quot; âœ&quot;"/>
  <result pre="100â€‰min 7 copies per reaction âœ&quot; âœ&quot; Suitable for home" exact="screening" post="but requiring clinical validation [45] â€ƒCepat Nasopharyngeal or oropharyngeal"/>
  <result pre="SARS-CoV and MERS-CoV. Table 3 TCM recommendations by guidelines for" exact="diagnosis" post="and treatment of COVID-19 (7th edition) [25]. Symptoms Potential"/>
  <result pre="MERS-CoV. Table 3 TCM recommendations by guidelines for diagnosis and" exact="treatment" post="of COVID-19 (7th edition) [25]. Symptoms Potential TCM Main"/>
  <result pre="diabetes, and pregnant women should speak to physicians before the" exact="treatment" post="â€ƒFatigue, fever Lian Hua Qing Wen Capsule (è¿žèŠ±æ¸…ç˜Ÿèƒ¶å›Š) Forsythia,"/>
  <result pre="diabetes, and pregnant women should speak to physicians before the" exact="treatment" post="Shu Feng Jie Du Capsule (ç–�é£Žè§£æ¯’èƒ¶å›Š) Bushy knotweed root,"/>
  <result pre="individuals and individuals with allergic constitution are prohibited from the" exact="treatment" post="Jin Hua Qing Gan Pill (é‡‘èŠ±æ¸…æ&quot;Ÿä¸¸) Honeysuckle flower, gypsum,"/>
  <result pre="individuals, and individuals with allergic constitution are prohibited from the" exact="treatment" post="Confirmed cases â€ƒMild/general/severe Qing Fei Pai Du Decoction (æ¸…è‚ºæŽ’æ¯’æ±¤)"/>
  <result pre="convulsions. Pregnant women and allergic individuals are prohibited from the" exact="treatment" post="Xing Nao Jing Injection (é†’è&quot;‘é�™æ³¨å°&quot;æ¶²) Musk, borneol, cape jasmine"/>
  <result pre="response, i.e., skin rash. Pregnant women are prohibited from the" exact="treatment" post="â€ƒSevere/critical Xue Bi Jing Injection (è¡€å¿…å‡€æ³¨å°&quot;æ¶²) Safflower, peony root,"/>
  <result pre="autoimmune response, i.e., itchiness. Pregnant women are prohibited from the" exact="treatment" post="Re Du Ning Injection (çƒ­æ¯’å®�æ³¨å°&quot;æ¶²) Wormwood, honeysuckle flower, cape"/>
  <result pre="skin rash, and itchiness. Allergic individuals are prohibited from the" exact="treatment" post="Tan Re Qing Injection (ç—°çƒ­æ¸…æ³¨å°&quot;æ¶²) Baical skullcap root, bear"/>
  <result pre="individuals, and individuals with allergic constitution are prohibited from the" exact="treatment" post="Sheng Mai Injection (ç&quot;Ÿè&quot;‰æ³¨å°&quot;æ¶²) Red ginseng, Ophiopogon, magnolia berry"/>
  <result pre="individuals, and individuals with allergic constitution are prohibited from the" exact="treatment" post="Shen Mai Injection (å�‚éº¦æ³¨å°&quot;æ¶²) Red ginseng, Ophiopogon N/A May"/>
  <result pre="individuals, and individuals with allergic constitution are prohibited from the" exact="treatment" post="Su He Xiang Pill (è‹�å�ˆé¦™ä¸¸) Storax, benzoin, borneol, musk,"/>
  <result pre="effects are not known. Pregnant women are prohibited from the" exact="treatment" post="An Gong Niu Huang Pill (å®‰å®«ç‰›é»&quot;ä¸¸) Buffalo horn, musk,"/>
  <result pre="2-3 trials for prophylaxis of COVID-19Phase 2-4 trials for the" exact="treatment" post="of COVID-19 [130â€&quot;140] â€ƒLopinavir HIV Proposed inhibition of 3CLpro"/>
  <result pre="HIV Proposed inhibition of 3CLpro Phase 2-4 trials for the" exact="treatment" post="of COVID-19 [159, 160] â€ƒRitonavir HIV Proposed inhibition of"/>
  <result pre="HIV Proposed inhibition of 3CLpro Phase 2-4 trials for the" exact="treatment" post="of COVID-19 [159, 160] â€ƒDarunavir HIV Inhibition of viral"/>
  <result pre="Inhibition of viral maturation pathways Phase 2-3 trials for the" exact="treatment" post="of pneumonia caused by COVID-19 [164] â€ƒCamostat mesylate Pancreatic"/>
  <result pre="(proposed) Inhibits viral RNA polymerase Phase 3 trials for the" exact="treatment" post="of COVID-19 [186, 188] â€ƒFavipiravir Influenza Inhibits RdRp Phase"/>
  <result pre="Influenza Inhibits RdRp Phase 3 and randomized trials for the" exact="treatment" post="of COVID-19 [138, 179â€&quot;182] â€ƒRibavirin HCV, RSV Inhibition of"/>
  <result pre="increased mutation in viral RNA Phase 2 trials for the" exact="treatment" post="of COVID-19 [168â€&quot;172] Biologics â€‰ â€‰ â€‰ â€‰ â€‰"/>
  <result pre="viral protein Phase 1 clinical trials for prevention of COVID-19" exact="infection" post="[237, 238] â€ƒB &amp;amp; T cell epitopes SARS-CoV Invoke"/>
  <result pre="secretion of soluble paracrine factors Phase 0-1 trials for the" exact="treatment" post="of COVID-19 [235, 236] TCM/herbal remedies â€ƒLian Hua Qing"/>
  <result pre="Wen Capsule Influenza Downregulates MCP-1 which decreases monocytes chemotaxis to" exact="infection" post="foci Phase 4 trials for the treatment of COVID-19"/>
  <result pre="monocytes chemotaxis to infection foci Phase 4 trials for the" exact="treatment" post="of COVID-19 [25, 252] â€ƒXue Bi Jing Injection Inflammation"/>
  <result pre="inflammatory cytokines TNF-Î± and IL-6 Phase 0-4 trials for the" exact="treatment" post="of COVID-19 [25, 232, 253] â€ƒRe Du Ning Injection"/>
  <result pre="Suppressing secretion of inflammatory mediators Phase 0 trial for the" exact="treatment" post="of COVID-19 [25, 254] â€ƒXi Yan Ping Injection HFMD,"/>
  <result pre="NF-ÎºB and MAPK-mediated inflammatory responses Phase 0 trial for the" exact="treatment" post="of COVID-19 [25, 255] â€ƒTan Re Qing Injection/Capsule URTI,"/>
  <result pre="NF-ÎºB and MAPK-mediated inflammatory responses Phase 0-4 trials for the" exact="treatment" post="of COVID-19 [25, 256] â€ƒShen Fu Injection Congestive heart"/>
  <result pre="protective effect against organ damage Phase 4 trial for the" exact="treatment" post="of COVID-19 [25, 257] Abbreviations: 3CLpro: 3C-like protease; COPD:"/>
 </snippets>
</snippetsTree>
